| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2012PLoSO...749702B |
| P356 | DOI | 10.1371/JOURNAL.PONE.0049702 |
| P932 | PMC publication ID | 3499488 |
| P698 | PubMed publication ID | 23166750 |
| P5875 | ResearchGate publication ID | 233725662 |
| P2093 | author name string | Yibang Chen | |
| Ravi Iyengar | |||
| Aislyn D W Boran | |||
| Shan Zhao | |||
| Gomathi Jayaraman | |||
| Joseph Seco | |||
| Sushmitha Reddy | |||
| Vinodh Jayaraman | |||
| P2860 | cites work | Apoptosis signal-regulating kinase 1 is involved not only in apoptosis but also in non-apoptotic cardiomyocyte death. | Q53711865 |
| Cholera toxin stimulation of human mammary epithelial cells in culture | Q72950883 | ||
| Deciphering the mammalian stress response - a stressful task | Q73171142 | ||
| Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines | Q74081713 | ||
| Structure of the membrane reconstituted transmembrane-juxtamembrane peptide EGFR(622-660) and its interaction with Ca2+/calmodulin | Q79247495 | ||
| Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment | Q24309071 | ||
| Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain | Q24794765 | ||
| The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain | Q27646344 | ||
| EGFR mutation and resistance of non-small-cell lung cancer to gefitinib | Q27824829 | ||
| Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab | Q27851587 | ||
| An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation | Q33733313 | ||
| Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy | Q33943421 | ||
| Understanding resistance to EGFR inhibitors-impact on future treatment strategies | Q34088424 | ||
| p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy | Q35039999 | ||
| Variants of 3T3 cells lacking mitogenic response to epidermal growth factor | Q35051611 | ||
| Human epithelial cell immortalization as a step in carcinogenesis | Q35131789 | ||
| Phosphatidylinositol-4,5-bisphosphate regulates epidermal growth factor receptor activation | Q35762279 | ||
| Transmembrane peptides as inhibitors of ErbB receptor signaling | Q35919443 | ||
| Epidermal growth factor receptor-mediated cell motility: phospholipase C activity is required, but mitogen-activated protein kinase activity is not sufficient for induced cell movement | Q36234800 | ||
| Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation | Q36288511 | ||
| ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4. | Q36490427 | ||
| An electrostatic engine model for autoinhibition and activation of the epidermal growth factor receptor (EGFR/ErbB) family | Q36493654 | ||
| Targeting the EGFR pathway for cancer therapy | Q36683460 | ||
| EGFR family: structure physiology signalling and therapeutic targets | Q37272623 | ||
| Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer | Q37274280 | ||
| Serum-free growth of human mammary epithelial cells: rapid clonal growth in defined medium and extended serial passage with pituitary extract | Q37565967 | ||
| EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors | Q37634595 | ||
| KRAS and BRAF: drug targets and predictive biomarkers | Q37815135 | ||
| Constitutive activation of neuregulin/ERBB3 signaling pathway in clear cell sarcoma of soft tissue | Q38581899 | ||
| p38 MAP kinase controls EGF receptor downregulation via phosphorylation at Ser1046/1047. | Q39896361 | ||
| Inactivation of p53 function in cultured human mammary epithelial cells turns the telomere-length dependent senescence barrier from agonescence into crisis. | Q40099043 | ||
| Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines | Q40106465 | ||
| Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells | Q40408766 | ||
| Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling. | Q40419018 | ||
| Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivo. | Q42806142 | ||
| The human epidermal growth factor receptor contains a juxtamembrane calmodulin-binding site. | Q42832751 | ||
| The intracellular juxtamembrane domain of the epidermal growth factor (EGF) receptor is responsible for the allosteric regulation of EGF binding | Q43131495 | ||
| Mitogen-activated protein kinase regulates early phosphorylation and delayed expression of Ca2+/calmodulin-dependent protein kinase II in long-term potentiation. | Q43732514 | ||
| A basic peptide within the juxtamembrane region is required for EGF receptor dimerization | Q45149243 | ||
| Ultraviolet light and osmotic stress: activation of the JNK cascade through multiple growth factor and cytokine receptors | Q46175993 | ||
| Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. | Q47448961 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e49702 | |
| P577 | publication date | 2012-01-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | A potential peptide therapeutic derived from the juxtamembrane domain of the epidermal growth factor receptor | |
| P478 | volume | 7 |
| Q52689258 | A dual-function epidermal growth factor receptor pathway substrate 8 (Eps8)-derived peptide exhibits a potent cytotoxic T lymphocyte-activating effect and a specific inhibitory activity. |
| Q64278999 | A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation |
| Q38970301 | Inhibiting epidermal growth factor receptor at a distance |
| Q36698771 | Oligomerization of the Sec7 domain Arf guanine nucleotide exchange factor GBF1 is dispensable for Golgi localization and function but regulates degradation. |
| Q30398451 | Targeting kinase signaling pathways with constrained peptide scaffolds |
Search more.